Hydrocortisone (Hydrocortisone Sodium Succinate)

Hydrocortisone sodium succinate injection is indicated for several acute and chronic conditions that require rapid glucocorticoid replacement or anti‑inflammatory action.

• Treatment of primary or secondary adrenal insufficiency, such as Addison’s disease.
• Management of acute adrenal crisis, including stress‑related cortisol deficiency.
• Rapid control of severe allergic reactions, including anaphylaxis.
• Supportive therapy for septic, hypovolemic, or anaphylactic shock.
• Adjunctive treatment of severe inflammatory disorders, such as vasculitis or severe asthma exacerbations.

• Hydrocortisone sodium succinate is a water‑soluble pro‑drug that is rapidly converted to cortisol after intravenous or intramuscular administration. The active cortisol binds intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and interacts with glucocorticoid response elements on DNA. This modulates transcription of multiple genes, resulting in decreased production of pro‑inflammatory cytokines, inhibition of leukocyte migration, and suppression of immune cell activation.

Adverse reactions to hydrocortisone injection vary in frequency and severity.

Common

• Transient hyperglycemia.
• Fluid retention and mild edema.
• Elevated blood pressure.
• Mood changes such as anxiety or insomnia.

Serious

• Severe infection or sepsis due to immunosuppression.
• Acute adrenal suppression after abrupt discontinuation.
• Gastrointestinal bleeding or ulceration.
• Allergic anaphylactoid reaction.

Clinicians should evaluate several safety considerations before initiating hydrocortisone sodium succinate therapy.

• Assess for active or latent infections; glucocorticoids can worsen bacterial, viral, or fungal diseases.
• Use the lowest effective dose and limit duration to reduce risk of systemic side effects.
• Monitor blood glucose in diabetic patients, as corticosteroids may raise glucose levels.
• Evaluate cardiovascular status, especially in patients with hypertension or heart failure, because fluid retention may exacerbate conditions.
• Consider tapering the dose when long‑term therapy is stopped to avoid adrenal insufficiency.
• Use with caution in pregnant or nursing women; safety data are limited.
• Review patient history for peptic ulcer disease or gastrointestinal bleeding risk.

Hydrocortisone injection can interact with several medicines, altering efficacy or safety.

Avoid

• Concomitant use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce glucocorticoid levels.
• Simultaneous administration of non‑steroidal anti‑inflammatory drugs (NSAIDs) or anticoagulants, which can increase risk of gastrointestinal bleeding.
• Live vaccines, because immunosuppression may diminish vaccine effectiveness.

Use with caution

• Antidiabetic agents, as corticosteroids may raise blood glucose and require dose adjustments.
• Antihypertensive drugs, particularly ACE inhibitors or diuretics, due to potential fluid retention.
• Anticoagulants (e.g., warfarin), because glucocorticoids can affect coagulation parameters.
• Antifungal azoles (e.g., ketoconazole) that inhibit cortisol metabolism, potentially increasing systemic exposure.